Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

Telik

Status and phase: Completed; Phase 2

Conditions: Carcinoma, Non-small-cell Lung

Treatments: Drug: TLK286

Study type: Interventional

Funder types: Industry

Identifiers

NCT00040638

TLK286.2014

Details and patient eligibility

About

The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologic or cytologic diagnosis of non-small cell lung carcinoma
• Progressed while on or after treatment on platinum-based regimen
• Patients may not have had more than one prior cytotoxic chemotherapy regimen
• Stage IV or IIIB
• Age at least 18 years
• Adequate liver and kidney function
• Adequate bone marrow function

Exclusion criteria

• Pregnancy or lactation
• Unstable medical conditions
• Chemotherapy, hormonal therapy, radiotherapy, radiopharmaceuticals or immunotherapy within 3 weeks of TLK286
• CNS metastasis unless controlled by treatment

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)